Simultaneous determination of the 13 antiretroviral agents: amprenavir, lopinavir, ritonavir, saquinavir and efavirenz in 14 human peripheral blood mononuclear cells by high-performance liquid 15 chromatography-mass spectrometry, J Chromatogr B Analyt Technol Biomed Life Sci, vol.16813, issue.17, pp.209-225, 2004. ,
Monitoring of lopinavir and ritonavir in 18 peripheral blood mononuclear cells, plasma, and ultrafiltrate using a selective and 19 highly sensitive LC/MS/MS assay, J Chromatogr B Analyt Technol Biomed Life Sci, vol.20850, issue.21, pp.249-58, 2007. ,
An enzyme immunoassay for the 22 quantification of plasma and intracellular lopinavir in HIV-infected patients, J Immunol, vol.23295, issue.24, pp.37-48, 2004. ,
Quantitative Immunoassay To Measure Plasma and Intracellular Atazanavir Levels: Analysis of Drug Accumulation in Cultured T Cells, Antimicrobial Agents and Chemotherapy, vol.51, issue.2, pp.405-416, 2007. ,
DOI : 10.1128/AAC.00730-06
The intracellular pharmacology of antiretroviral protease inhibitors, Journal of Antimicrobial Chemotherapy, vol.54, issue.6, pp.982-90, 2004. ,
DOI : 10.1093/jac/dkh487
Protein Binding in Antiretroviral Therapies, AIDS Research and Human Retroviruses, vol.19, issue.9, pp.825-860, 2003. ,
DOI : 10.1089/088922203769232629
Genetic Variation in Drug Transporters in Ethnic Populations, Clinical Pharmacology & Therapeutics, vol.453, issue.3, pp.412-418, 2008. ,
DOI : 10.1038/clpt.2008.98
Expression and Functionality of Anti-Human Immunodeficiency Virus and Anticancer Drug Uptake Transporters in Immune Cells, Journal of Pharmacology and Experimental Therapeutics, vol.324, issue.2, pp.558-67, 2008. ,
DOI : 10.1124/jpet.107.131482
Expression of adenosine triphosphate- 37 binding cassette (ABC) drug transporters in peripheral blood cells: relevance for 38 physiology and pharmacotherapy, Abcg2/Bcrp1 mediates the polarized transport of 40 antiretroviral nucleosides abacavir and zidovudine, pp.449-70, 2007. ,
Modulation of human BCRP (ABCG2) activity by anti-HIV drugs, Journal of Antimicrobial Chemotherapy, vol.59, issue.2, pp.238-283, 2007. ,
DOI : 10.1093/jac/dkl474
Mechanisms of drug transfer across 45 the human placenta-a workshop report Cell entry and 47 export of nucleoside analogues, Placenta Virus Res Feb, vol.231075707, issue.2, pp.151-64, 2002. ,
Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules, Current Opinion in Infectious Diseases, vol.15, issue.1, 2002. ,
DOI : 10.1097/00001432-200202000-00002
Choroid plexus controls brain availability of anti-HIV nucleoside analogs via pharmacologically inhibitable organic anion transporters, AIDS, vol.17, issue.10, pp.1473-85, 2003. ,
DOI : 10.1097/00002030-200307040-00008
Association between ABCC2 gene 7 haplotypes and tenofovir-induced proximal tubulopathy, J Infect Dis, vol.194, issue.9, pp.8-1481, 2006. ,
Concentrations of zidovudine- and lamivudine-triphosphate according to cell type in HIV-seronegative adults, AIDS, vol.21, issue.14, pp.1849-54, 200711-09-12. ,
DOI : 10.1097/QAD.0b013e3282741feb
Compartmental kinetics of intracellular 13 tenofovir [abstract n° 754] Conference on retrovi ruses and Opportunistic Infections 14, pp.341-67, 2006. ,
Thymidine and 3'-azido-3'-deoxythymidine 16 metabolism in human peripheral blood lymphocytes and monocyte-derived 17 macrophages. A study of both anabolic and catabolic pathways, J Biol Chem, 1992. ,
Lower 20 levels of nucleoside analog triphosphates in primary human macrophages compared 21 to human lymphocytes could impair potency of antiretroviral drugs in human viral 22 reservoirs. HIV DART, 1223. ,
Therapeutic strategies towards HIV-1 infection in macrophages, Antiviral Research, vol.71, issue.2-3, pp.293-300, 2006. ,
DOI : 10.1016/j.antiviral.2006.05.015
Differential modulation of P- 26 glycoprotein expression and activity by non-nucleoside HIV-1 reverse transcriptase 27 inhibitors in cell culture, Pharmaceutical Research, vol.19, issue.7, pp.1038-1083, 2002. ,
DOI : 10.1023/A:1016430825740
Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs, Pharmacology & Therapeutics, vol.112, issue.2, pp.457-73, 2006. ,
DOI : 10.1016/j.pharmthera.2006.04.009
Pharmacogenetic Characteristics of Indinavir, Zidovudine, and Lamivudine Therapy in HIV-Infected Adults, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.42, issue.4, pp.441-450, 2006. ,
DOI : 10.1097/01.qai.0000225013.53568.69
P-glycoprotein and MRP1 expression and reduced ritonavir and saquinavir accumulation in HIV-infected individuals, Journal of Antimicrobial Chemotherapy, vol.50, issue.4, pp.583-591, 2002. ,
DOI : 10.1093/jac/dkf161
Transporters and drug therapy: implications for drug 37 disposition and disease Pharmacogenetics of anti-HIV drugs, Clin Pharmacol Ther Annu Rev Pharmacol Toxicol, vol.7848, issue.40, pp.260-77, 2005. ,
The effect of ABCB1 polymorphism on the 41 pharmacokinetics of saquinavir alone and in combination with ritonavir Clin 42 An MDR1-3435 variant is associated 44 with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 45 infected children Intracellular and plasma 47 pharmacokinetics of nelfinavir and M8 in HIV-infected patients: relationship with P- 48 glycoprotein expression, Pharmacol Ther Aids Mar Antivir Ther Feb, vol.821995707, issue.441, pp.389-95, 2004. ,
Intracellular Concentration of Protease Inhibitors in HIV-1--Infected Patients: Correlation with MDR-1 Gene Expression and Low Dose of Ritonavir, HIV Clinical Trials, vol.14, issue.4, pp.493-501, 2002. ,
DOI : 10.1093/carcin/20.3.407
Clinical and Genetic Determinants of Intracellular Tenofovir Diphosphate Concentrations in HIV-Infected Patients, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.47, issue.3 ,
DOI : 10.1097/QAI.0b013e31815e7478
Intracellular pharmacokinetics 10 of tenofovir diphosphate, carbovir triphosphate, and lamivudine triphosphate in 11 patients receiving triple-nucleoside regimens, J Acquir Immune Defic Syndr, 2005. ,
Zidovudine phosphorylation determined 14 sequentially over 12 months in human immunodeficiency virus-infected patients with 15 or without previous exposure to antiretroviral agents Zidovudine triphosphate and 18 lamivudine triphosphate concentration-response relationships in HIV-infected 19 persons Measurement of intracellular 21 didanosine and tenofovir phosphorylated metabolites and possible interaction of the 22 two drugs in human immunodeficiency virus-infected patients. Antimicrob Agents 23 Chemother, Antimicrob Agents Chemother Aids Clin Pharmacokinet, vol.1645144943, issue.27, pp.976-80, 2000. ,
Intracellular nucleoside triphosphate 28 concentrations in HIV-infected patients on dual nucleoside reverse transcriptase 29 inhibitor therapy Breilh D, Pellegrin I, Rouzes A, et al. Virological, intracellular and plasma 31 pharmacological parameters predicting response to lopinavir/ritonavir (KALEPHAR 32 study), Antivir Ther Aids, vol.1218, issue.33, pp.981-987, 2004. ,
Once-daily dosing of saquinavir 34 soft-gel capsules and ritonavir combination in HIV-1-infected patients (IMEA015 35 study), Antivir Ther, vol.9, issue.36, pp.247-56, 2004. ,
Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients, Pharmacogenetics and Genomics, vol.15, issue.1, pp.1-5, 2005. ,
DOI : 10.1097/01213011-200501000-00001
Intracellular pharmacokinetics of once 40 versus twice daily zidovudine and lamivudine in adolescents. Antimicrob Agents 41 Chemother, pp.3516-3538, 2007. ,
The impact of sex and contraceptive therapy on the plasma and intracellular pharmacokinetics of zidovudine, AIDS, vol.20, issue.14, pp.1833-1874, 2006. ,
DOI : 10.1097/01.aids.0000244202.18629.36
Systemic Pharmacokinetics and Cellular Pharmacology of Zidovudine in Human Immunodeficiency Virus Type 1???Infected Women and Newborn Infants, The Journal of Infectious Diseases, vol.180, issue.6, pp.1844-50, 1999. ,
DOI : 10.1086/315152
The effect of zidovudine dose on the 49 formation of intracellular phosphorylated metabolites, AIDS, vol.105707, issue.12, pp.1361-1368, 1996. ,
Pharmacokinetics of Antiretroviral Regimens Containing Tenofovir Disoproxil Fumarate and Atazanavir-Ritonavir in Adolescents and Young Adults with Human Immunodeficiency Virus Infection, Antimicrobial Agents and Chemotherapy, vol.52, issue.2 ,
DOI : 10.1128/AAC.00761-07
Intracellular and plasma efavirenz concentrations in HIV-infected patients switching from successful protease inhibitor-based highly active antiretroviral therapy (HAART) to efavirenz-based HAART (SUSTIPHAR Study), Journal of Antimicrobial Chemotherapy, vol.58, issue.5, pp.1090-1093, 2006. ,
DOI : 10.1093/jac/dkl348
Intracellular and plasma pharmacokinetics 9 of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human 10 immunodeficiency virus-infected patients The plasma and intracellular 13 steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients, Antimicrob Agents Chemother Crommentuyn KM, vol.489, issue.15, pp.11-2388, 2004. ,
High levels of zidovudine (AZT) 16 and its intracellular phosphate metabolites in AZT-and AZT-lamivudine-treated 17 newborns of human immunodeficiency virus-infected mothers. Antimicrob Agents 18 Chemother, pp.2555-63, 2008. ,
Pharmacokinetic and Pharmacodynamic Characteristics of Emtricitabine Support Its Once Daily Dosing for the Treatment of HIV Infection, AIDS Research and Human Retroviruses, vol.20, issue.11, pp.1173-1195, 2004. ,
DOI : 10.1089/aid.2004.20.1173
Intracellular carbovir triphosphate levels in patients taking abacavir once a day, AIDS, vol.16, issue.8, pp.1196-1203, 2002. ,
DOI : 10.1097/00002030-200205240-00021
In Vivo Antagonism with Zidovudine plus Stavudine Combination Therapy, The Journal of Infectious Diseases, vol.182, issue.1, pp.321-326, 2000. ,
DOI : 10.1086/315683
Intracellular Metabolism of Zidovudine and Stavudine in Combination, Journal of Infectious Diseases, vol.174, issue.3, pp.671-673, 1996. ,
DOI : 10.1093/infdis/174.3.671
Effects of drugs on 2',3'-dideoxy-2',3'- 30 didehydrothymidine phosphorylation in vitro, Antimicrob Agents Chemother, 1997. ,
A pilot pharmacokinetic study in HIV 33 infected patient receiving tenofovir disoproxil fumarate (TDF): Investigation of 34 systemic and intracellular interaction between TDF and abacavir, lamivudine or 35 lopinavir/ritonavir Early virologic nonresponse to 37 tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects, Antimicrob Agents Chemother J 38 Infect Dis, vol.9192, issue.11, pp.36-106, 2005. ,
The effect of lopinavir/ritonavir on the 40 renal clearance of tenofovir in HIV-infected patients, Clin Pharmacol Ther, 2008. ,
Influence of prior exposure to 43 zidovudine on stavudine phosphorylation in vivo and ex vivo. Antimicrob Agents 44 Chemother, Feb, vol.45, issue.2, pp.577-82, 2001. ,
Efficacy and tolerability of 46 stavudine plus lamivudine in treatment-naive and treatment-experienced patients 47 with HIV-1 infection, Ann Intern Med, vol.1295707, issue.7, pp.525-556, 1998. ,
Fatal Lactic Acidosis and Acute Renal Failure after Addition of Tenofovir to an Antiretroviral Regimen Containing Didanosine, Clinical Infectious Diseases, vol.36, issue.8 ,
DOI : 10.1086/368313
Didanosine-Associated Toxicity, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.35, issue.4 ,
DOI : 10.1097/00126334-200404010-00013
Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir, Journal of Antimicrobial Chemotherapy, vol.57, issue.5, pp.806-815, 2006. ,
DOI : 10.1093/jac/dkl045
High virological failure rate in HIV patients after switching to a regimen with two nucleoside reverse transcriptase inhibitors plus tenofovir, AIDS, vol.19, issue.7, pp.695-703, 2005. ,
DOI : 10.1097/01.aids.0000166092.39317.42
The durability of virological success of 15 tenofovir and didanosine dosed at either 400 or 250 mg once daily, HIV Med, 2005. ,
Effect of Lamivudine on the plasma and 18 intracellular pharmacokinetics of apricitabine, a novel nucleoside reverse 19 transcriptase inhibitor, in healthy volunteers, Antimicrob Agents Chemother, 2007. ,
Activity, safety, and immunological effects 22 of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 23 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307, AIDS Res Hum Retroviruses, vol.2420, issue.9, pp.916-942, 2004. ,
Effect of Hydroxyurea and Dideoxyinosine on Intracellular 3???-Deoxyadenosine-5???-triphosphate Concentrations in HIV-Infected Patients, AIDS Research and Human Retroviruses, vol.23, issue.11, pp.1360-1365, 2007. ,
DOI : 10.1089/aid.2007.0078
Abacavir and mycophenolic acid, an 29 inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic 30 anti-HIV activity, J Acquir Immune Defic Syndr Aug, vol.1521, issue.5, pp.362-70, 1999. ,
The metabolism, pharmacokinetics and mechanisms 32 of antiviral activity of ribavirin against hepatitis C virus, Cell Mol Life Sci, vol.63, pp.33-40, 2006. ,
Effect of ribavirin on 35 intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase 36 inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: 37 results of a randomized clinical study, Antimicrob Agents Chemother, vol.49, issue.10, pp.38-3997, 2005. ,
Pharmacokinetic evaluation of the effects of 40 ribavirin on zidovudine triphosphate formation: ACTG 5092s Study Team, HIV Med, vol.418, issue.5, pp.288-94, 2007. ,
Effect of ribavirin on zidovudine 43 efficacy and toxicity in vitro: a concentration-dependent interaction, AIDS Res Hum, vol.4414, issue.18, pp.1661-1668, 1998. ,
Ribavirin antagonizes the effect of azidothymidine on HIV replication, Science, vol.235, issue.4794, pp.1376-1385, 1987. ,
DOI : 10.1126/science.2435003
Mechanism of the potentiating effect of 48 ribavirin on the activity of 2',3'-dideoxyinosine against human immunodeficiency virus, J Biol Chem Nov, vol.152665707, issue.32, pp.21509-21523, 1991. ,
Risk Factors for Symptomatic Mitochondrial Toxicity in HIV/Hepatitis C Virus-Coinfected Patients During Interferon Plus Ribavirin-Based Therapy, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.40, issue.1, pp.47-52, 2005. ,
DOI : 10.1097/01.qai.0000174649.51084.46
HCV-coinfected patients receiving ribavirin, Antivir Ther Feb, vol.59, issue.1, pp.133-141, 2004. ,
Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.58, issue.5, 2006. ,
DOI : 10.1093/jac/dkl379
Effect of quercetin on the 11 plasma and intracellular concentrations of saquinavir in healthy adults, Pharmacotherapy, vol.1226, issue.9, pp.1255-61, 2006. ,
Intracellular accumulation of human 14 immunodeficiency virus protease inhibitors, Antimicrob Agents Chemother, 2002. ,
Low response to pegylated interferon 17 plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir, p.18 ,
Correlates of zidovudine 20 phosphorylation with markers of HIV disease progression and drug toxicity, Antivir Ther Aids, vol.138, issue.216, pp.429-466, 1994. ,
The Pharmacology of Antiretroviral Nucleoside and Nucleotide Reverse Transcriptase Inhibitors, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.39, issue.Supplement 1, pp.1-23, 2005. ,
DOI : 10.1097/01.qai.0000168882.67942.3f
Concentration-controlled compared with conventional antiretroviral therapy for HIV infection, AIDS, vol.16, issue.4, pp.551-60, 0278. ,
DOI : 10.1097/00002030-200203080-00006
Switching Effective Antiretroviral Therapy: A Review, Clinical Infectious Diseases, vol.35, issue.10, pp.1219-1249, 2002. ,
DOI : 10.1086/343050
Induction-maintenance antiretroviral strategies to reduce long-term 31 toxicity, J HIV Ther Feb, vol.8, issue.1, pp.11-15, 2003. ,
Effect of Adherence to HAART on Virologic Outcome and on the Selection of Resistance-Conferring Mutations in NNRTI- or PI-Treated Patients, HIV Clinical Trials, vol.5, issue.1, pp.282-92, 2007. ,
DOI : 10.1128/AAC.45.4.1086-1093.2001
Predictors of HIV drug-resistance 36 mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy, J 37 Infect Dis Feb, vol.1191, issue.3, pp.339-386, 2005. ,
Explaining variability in the 39 relationship between antiretroviral adherence and HIV mutation accumulation, p.40 ,
Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients, Journal of Antimicrobial Chemotherapy, vol.53, issue.1, pp.10-14, 2004. ,
DOI : 10.1093/jac/dkh013
HIV-associated Lipodystrophy Syndrome: Description and Pathogenesis, Journal of Infection, vol.46, issue.3, pp.149-54, 2003. ,
DOI : 10.1053/jinf.2002.1102
The role of efavirenz 46 compared with protease inhibitors in the body fat changes associated with highly 47 active antiretroviral therapy, J Antimicrob Chemother, vol.625707, issue.2, pp.234-279, 2008. ,
HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options, Journal of Antimicrobial Chemotherapy, vol.62, issue.4, p.3, 2008. ,
DOI : 10.1093/jac/dkn251
Complications associated with NRTI therapy: update on 4 clinical features and possible pathogenic mechanisms, Antivir Ther, vol.9, issue.6, pp.5-849, 2004. ,
Nucleoside Reverse Transcriptase Inhibitor Usage and the Incidence of Peripheral Neuropathy in HIV/AIDS Patients, Antiviral Chemistry and Chemotherapy, vol.16, issue.5, pp.281-285, 2003. ,
DOI : 10.1177/095632020301400507
Metabolic abnormalities in skeletal muscle of patients receiving zidovudine therapy observed by 31P in vivo magnetic resonance spectroscopy., Journal of Clinical Investigation, vol.96, issue.1, pp.126-157, 1995. ,
DOI : 10.1172/JCI118012
Long-term toxicity/activity profile of 13 2',3'-dideoxyinosine in AIDS or AIDS-related complex, Lancet, vol.336, issue.8714, pp.14-526, 1990. ,
Hematologic toxicity of zidovudine in HIV-infected 16 patients, Am Fam Physician, vol.41, issue.5, pp.1521-1529, 1990. ,
Tenofovir-Associated Fanconi Syndrome: Review of the FDA Adverse Event Reporting System, AIDS Patient Care and STDs, vol.22, issue.2, pp.99-103, 2008. ,
DOI : 10.1089/apc.2007.0052
Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals, Annals of Internal Medicine, vol.143, issue.10, pp.714-735, 2005. ,
DOI : 10.7326/0003-4819-143-10-200511150-00008
Incidence of liver 23 injury after beginning antiretroviral therapy with efavirenz or nevirapine, HIV Clin, vol.244, issue.2, pp.115-135, 2003. ,
Serious adverse cutaneous and 26 hepatic toxicities associated with nevirapine use by non-HIV-infected individuals, p.27 ,
Risk of side effects associated with the use of nevirapine in treatment-na??ve patients, with respect to gender and CD4 cell count, HIV Medicine, vol.19, issue.1, pp.14-22, 2008. ,
DOI : 10.1111/j.1468-1293.2008.00513.x
Pathogenesis of HIV-1-protease 32 inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. 33 Lancet, pp.1881-1884, 1998. ,
An inhibitor of HIV-1 protease 35 modulates proteasome activity, antigen presentation, and T cell responses, Proc Natl, p.36 ,
The sterol regulatory element-binding protein pathway: control of lipid homeostasis through regulated intracellular transport, Current Opinion in Lipidology, vol.12, issue.3, pp.261-267, 2001. ,
DOI : 10.1097/00041433-200106000-00004
The Mechanism of Insulin Resistance Caused by HIV Protease Inhibitor Therapy, Journal of Biological Chemistry, vol.275, issue.27, pp.20251-20255, 2000. ,
DOI : 10.1074/jbc.C000228200
Mechanisms of HIV and nucleoside reverse transcriptase inhibitor 43 injury to mitochondria, Antivir Ther, vol.10, issue.2, pp.47-52, 2005. ,
Population pharmacokinetics 45 and pharmacodynamics of zidovudine in HIV-infected infants and children, J Clin Feb, vol.4643, issue.2, pp.133-173, 2003. ,
Clinical pharmacokinetics of zidovudine: inter and intraindividual variability and relationship to long term efficacy and toxicity, European Journal of Clinical Pharmacology, vol.I, issue.2, p.49 ,
DOI : 10.1007/BF00315509